A phase 3b, randomized, open-label assessment of response to various doses of atomoxetine hydrochloride in Korean pediatric outpatients with attention-deficit/hyperactivity disorder.

Trial Profile

A phase 3b, randomized, open-label assessment of response to various doses of atomoxetine hydrochloride in Korean pediatric outpatients with attention-deficit/hyperactivity disorder.

Completed
Phase of Trial: Phase III

Latest Information Update: 27 Jan 2010

At a glance

  • Drugs Atomoxetine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 27 Jan 2010 Actual number of patients changed from 154 to 153 as reported by ClinicalTrials.gov.
    • 25 Nov 2008 Planned number of patients changed from 150 to 154, according to ClinicalTrials.gov.
    • 25 Nov 2008 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top